Vivos Inc (RDGL)

[kayak_wench]

New radiogel paper out with 6 of the 8 authors from Harvard medical school/Massachusetts General Hospital. Paper is not about how good radiogel works its about how to model the radiological dose resulting from treating with radiogel. I found it interesting in that radiogel dose is not uniform. Seems obvious now that i have read that given a needle is distributing the gel from a point so does is highest at the point of the needle and then decreases as the gel spreads from the point of the needle. Basically the paper concludes that there is a need to improve the process by which radiogel and all other brachytherapies dose and application are planned to maximize uniformity of dose within the tumor. So a nerdy paper for the medical community not investors. I suppose all investors should care about is that five researchers associated with Harvard medical school thought studying dose uniformity of radiogel was a worthy research article. Almost seems like these guys feel radiogel is destined for human use.

FYI, research was done using University of Missouri clinical trial data, which is pretty old. But the data is good months/years after it is gathered. I think what tipped the scale for these people to pursue funding to do this (they had NIH grants to write and do their research...obviously the dog data was provided/funded by Vivos back during the clinical trial) is their belief that radiogel will get approval for human use. If radiogel isn't eventually approved for human use then the importance/meaningfulness of this article is dramatically decreased.

https://iopscience.iop.org/article/10.1088/1361-6560/ad67a4/meta